{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:57:37Z","timestamp":1772827057996,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Anti-tumor necrosis factor (TNF) therapies have been the mainstay of inflammatory bowel disease (IBD) treatment for nearly 2 decades. Therapies with novel mechanisms of action have been recently developed. This study compared healthcare resource utilization (HRU) and costs incurred while switching from an initial anti-TNF to another anti-TNF versus switching to vedolizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with IBD who switched from initial anti-TNF to another anti-TNF or vedolizumab were identified from Truven MarketScan claims database (January 1, 2000\u2013September 30, 2017). Patient characteristics were assessed during the 6-month period before the initiation date of the switched-to treatment (index date). Adjusted analyses of all-cause and disease-related HRU and costs during the 6-month period after the index date (study period) were performed. Anti-TNF and vedolizumab switchers with Crohn\u2019s disease (CD) and ulcerative colitis (UC) were separately compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 502 vedolizumab, 1708 adalimumab, 755 infliximab, and 703 other switchers with CD and 461, 428, 311, and 148 with UC, respectively, were identified. Patient demographics were similar across cohorts. Total all-cause costs were significantly higher for vedolizumab than adalimumab, infliximab, and certolizumab switchers in the CD cohort and adalimumab and infliximab in the UC cohort. In both cohorts, adalimumab and other switchers had fewer all-cause and IBD-related outpatient visits than vedolizumab switchers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CD\/UC patients who switched to vedolizumab from initial anti-TNF had higher total and treatment costs than patients who switched to another anti-TNF, except for UC patients who switched to golimumab. Prospective studies should be conducted to confirm these findings.<\/jats:p><\/jats:sec>","DOI":"10.1093\/crocol\/otaa031","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T19:11:11Z","timestamp":1587582671000},"source":"Crossref","is-referenced-by-count":4,"title":["Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab"],"prefix":"10.1093","volume":"2","author":[{"given":"Michael","family":"Chiorean","sequence":"first","affiliation":[{"name":"Digestive Disease Institute, Virginia Mason Medical Center , Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Afzali","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, The Ohio State University Wexner Medical Center , Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond K","family":"Cross","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Program, University of Maryland School of Medicine , Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dendy","family":"Macaulay","sequence":"additional","affiliation":[{"name":"Analysis Group , New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Griffith","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Wang","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Garcia-Horton","sequence":"additional","affiliation":[{"name":"Analysis Group , New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.crohns.2014.02.025","article-title":"Future directions in inflammatory bowel disease management","volume":"8","author":"D\u2019Haens","year":"2014","journal-title":"J Crohns Colitis."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3748\/wjg.v22.i3.1017","article-title":"How to predict clinical relapse in inflammatory bowel disease patients","volume":"22","author":"Liverani","year":"2016","journal-title":"World J Gastroenterol."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1756283X10373176","article-title":"Anti-adhesion molecule therapy for inflammatory bowel disease","volume":"3","author":"Ghosh","year":"2010","journal-title":"Therap Adv Gastroenterol."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5009\/gnl14226","article-title":"Current and emerging biologics for ulcerative colitis","volume":"9","author":"Park","year":"2015","journal-title":"Gut Liver."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4240\/wjgs.v8.i5.363","article-title":"Inflammatory bowel disease surgery in the biologic era","volume":"8","author":"Ferrari","year":"2016","journal-title":"World J Gastrointest Surg."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/apt.12727","article-title":"Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn\u2019s disease","volume":"39","author":"Rubin","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/apt.12507","article-title":"Review article: immunogenicity of anti-TNF biologics in IBD\u2014the role of patient, product and prescriber factors","volume":"38","author":"Moss","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2146\/ajhp140449","article-title":"Vedolizumab: an integrin-receptor antagonist for treatment of Crohn\u2019s disease and ulcerative colitis","volume":"72","author":"Hahn","year":"2015","journal-title":"Am J Health Syst Pharm."},{"key":"2023031013051926800_","article-title":"AGA Institute care pathway for the identification, assessment and initial medical treatment of ulcerative colitis: clinical care pathway","volume-title":"IBD & Bowel Disorders Guidelines","author":"Association","year":"2015"},{"key":"2023031013051926800_","article-title":"AGA Institute guidelines for the identification, assessment and initial medical treatment in Crohn\u2019s disease: clinical decision support tool","volume-title":"IBD & Bowel Disorders Guidelines","author":"Association","year":"2019"},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/ecco-jcc\/jjz046.001","article-title":"OP34 VARSITY: a double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis","volume":"13","author":"Schreiber","year":"2019","journal-title":"J Crohn\u2019s Colitis."},{"key":"2023031013051926800_","article-title":"An efficacy and safety study of vedolizumab intravenous (IV) compared to adalimumab subcutaneous (SC) in participants with ulcerative colitis","author":"Takeda","year":"2019","journal-title":"ClinicalTrialsgov."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care."},{"key":"2023031013051926800_","volume-title":"Consumer Price Index","author":"United States Bureau of Labor Statistics"},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1524-4733.2008.00335.x","article-title":"Loss of treatment response to infliximab maintenance therapy in Crohn\u2019s disease: a payor perspective","volume":"11","author":"Wu","year":"2008","journal-title":"Value Health."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2036.2009.04101.x","article-title":"Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab","volume":"30","author":"Ma","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"the real-world effectiveness and safety of vedolizumab for moderate-severe Crohn\u2019s disease: results from the US VICTORY consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"2023031013051926800_","first-page":"S588","article-title":"Utilizing a Markov model to determine the cost-effectiveness of vedolizumab compared to adalimumab for patient\u2019s with ulcerative colitis after loss of response to infliximab","volume":"152","author":"Schneider","year":"2017","journal-title":"Gastroenterology"},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/gutjnl-2011-301971","article-title":"Factors affecting outcomes in Crohn\u2019s disease over 15 years","volume":"61","author":"Cosnes","year":"2012","journal-title":"Gut."},{"key":"2023031013051926800_","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s12325-019-01095-1","article-title":"Analysis of safety, medical resource utilization, and treatment costs by drug class for management of inflammatory bowel disease in the united states based on insurance claims data","volume":"36","author":"Long","year":"2019","journal-title":"Adv Ther."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otaa031\/33140541\/otaa031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/2\/2\/otaa031\/49501832\/crohnscolitis360_2_2_otaa031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/2\/2\/otaa031\/49501832\/crohnscolitis360_2_2_otaa031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T06:57:38Z","timestamp":1696057058000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otaa031\/5826505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otaa031","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,4,1]]},"article-number":"otaa031"}}